Clinical Trial Results:
A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat® inhaler, after 4 weeks of once daily [5 µg in the evening (2 actuations of 2.5 µg)] or twice daily [2.5 µg in the morning and evening (2 actuations of 1.25 µg)] administration in patients with moderate persistent asthma.
Summary
|
|
EudraCT number |
2012-001873-10 |
Trial protocol |
AT HU DE SI |
Global completion date |
20 Jun 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Apr 2016
|
First version publication date |
30 Apr 2016
|
Other versions |
|
Summary report(s) |
Trial Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.